University of Southern California

BanyanGlobal Family Business Advisors Elects Ben Francois as New Managing Partner

Retrieved on: 
torsdag, maj 30, 2024
Consulting, Small Business, Professional Services, University of Pennsylvania, University, Publication, Harvard Business Review, University of Southern California, FFI, Face, Culture, Environment, Family, Management

BanyanGlobal Family Business Advisors partner Ben Francois has been named the second managing partner in the firm’s twelve-year history.

Key Points: 
  • BanyanGlobal Family Business Advisors partner Ben Francois has been named the second managing partner in the firm’s twelve-year history.
  • Lachenauer helped build Banyan into the world’s preeminent family business advisory firm.
  • Francois assumes the role of managing partner after having been with Banyan six years.
  • Francois speaks frequently on family business topics such as family business and family office governance, next generation development, and succession planning.

Leading Lower Middle-Market Specialist Investment Firm Star Mountain Capital Adds Bryan Johnson as a Managing Director in Los Angeles, Bolstering its Secondaries and Investor Solutions Team

Retrieved on: 
tisdag, maj 28, 2024
Finance, Consulting, Banking, Professional Services, Asset Management, Chemical engineering, CFA Institute, AQR, University, Chartered Alternative Investment Analyst, AQR Capital, Ageing, University of Southern California, MBA, Infineon Technologies, CAIA, Dimensional Fund Advisors, RIA, CFA, RIAS, Arizona State University, FINRA, Multimedia, Star, Financial services

View the full release here: https://www.businesswire.com/news/home/20240528877824/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240528877824/en/
    Bryan Johnson, Star Mountain Capital Managing Director (Photo: Business Wire)
    Bryan Johnson has nearly 20 years of leadership experience advising and consulting on strategic investment solutions to some of the world’s largest and most sophisticated wealth managers, family offices and high-net-worth individuals.
  • “I was also intrigued to learn how large and highly fragmented the lower middle-market is at nearly 50% of the U.S. economy.
  • Mr. Johnson is a Chartered Financial Analyst (CFA) charterholder and also holds the Chartered Alternative Investment Analyst (CAIA) designation.
  • He is a member of the CFA Institute and CFA Society Los Angeles, which he has lectured for since 2011.

New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines’ ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis

Retrieved on: 
söndag, maj 19, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Taste, Patient, Physical examination, Spasm, Lung, Vital signs, American Thoracic Society, PPF, University, TLC, Disease, Conference, University of Southern California, Idiopathic pulmonary fibrosis, QLF, Pulmonary fibrosis, ATS, IPF, Pharmaceutical industry

Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial that demonstrate the company’s lead investigational candidate, ENV-101, improved lung function and reversed key measures of lung fibrosis in patients with idiopathic pulmonary fibrosis (IPF) over a 12-week period.

Key Points: 
  • Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial that demonstrate the company’s lead investigational candidate, ENV-101, improved lung function and reversed key measures of lung fibrosis in patients with idiopathic pulmonary fibrosis (IPF) over a 12-week period.
  • They slow the decline of lung function, but do not stop or reverse it, and they have tolerability issues that limit their long-term use in most patients.
  • In ENV-101-treated patients, 80% experienced an increase in TLC while 70% of patients who received placebo showed a decrease in TLC.
  • Endeavor BioMedicines recently announced the closing of a $132.5 million Series C financing that will support clinical development of ENV-101 in IPF and PPF.

HCAP Partners Elevates Investment Team

Retrieved on: 
onsdag, maj 8, 2024
HCAP, University of Southern California, University, Political science, Wine, Investment, Santander Bank, Morgan Stanley, Health, Wealth management, Dean, Business school, Columbia University, Business, Learning, Risk management, Mathematics, CFA, Citigroup, SAN, Security (finance)

SAN DIEGO, May 8, 2024 /PRNewswire/ -- HCAP Partners, a California-based private equity firm and nationally recognized impact investor, is pleased to announce the promotion of Jessica Kim and Ben Consoli to Vice President and the addition of Senior Associate Chenjing Wang to its investment team.The promotions of Jessica and Ben and hiring of Chenjing signify the continuation of the firm's growth. As HCAP expands its impact in 2024 and beyond, their collective passion and expertise will be invaluable to the firm's success.

Key Points: 
  • SAN DIEGO, May 8, 2024 /PRNewswire/ -- HCAP Partners , a California-based private equity firm and nationally recognized impact investor, is pleased to announce the promotion of Jessica Kim and Ben Consoli to Vice President and the addition of Senior Associate Chenjing Wang to its investment team.
  • "We're thrilled to have Jessica, Ben, and Chenjing at HCAP," said Tim Bubnack, Managing Partner at HCAP.
  • After completing the fellowship and her graduate studies, Jessica joined HCAP's investment team as a Senior Associate and was promoted to Vice President.
  • Before joining HCAP, Chenjing was on the credit team at Morgan Stanley covering corporate and real estate lending transactions and fund-level equity investments.

CIRM Awards $11.8 Million Grant for Clinical Trial in High-Grade Glioma Including Glioblastoma Using DB107, a Novel DGM7™ Genetic Biomarker-Guided Gene Therapy

Retrieved on: 
tisdag, april 30, 2024
University of Southern California, Efficacy, University, UCSD, Radiation, Resection, Regenerative medicine, HGG, TMZ, Doctor of Philosophy, RRV, GBM, WGS, Glioblastoma, Artificial intelligence, Depression, CIRM, UCSF, USC, Intravenous therapy, Neoplasm, Clinical trial, Medicine, SHROOM3, Whole genome sequencing, SAN, Medical imaging

We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.

Key Points: 
  • We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.
  • DB107 consists of two components: DB107–RRV (vocimagene amiretrorepvec) as a prodrug activator gene therapy and DB107–FC (extended-release 5–fluorocytosine [5–FC]) as an oral prodrug.
  • Retrospective analysis of an earlier randomized clinical trial in patients with recurrent HGG suggested improved overall survival in DGM7–positive patients treated with DB107.
  • "We are excited to conduct this novel trial which will be investigating several new approaches for the first time in patients with newly–diagnosed high–grade glioma.

BASF and University of California, Berkeley, celebrate their successful 10-year collaboration

Retrieved on: 
tisdag, april 23, 2024
Stanford University, University of Southern California, University, University of California, Irvine, BASF, Research, Partnership, University of California, History, AFL–CIO, Patent, Chemistry, University of California, Berkeley, Ministry of Energy, Associate, UC, California Institute of Technology

The multidisciplinary research center is focused on evaluating new materials, technologies and processes that will help address key sustainability challenges.

Key Points: 
  • The multidisciplinary research center is focused on evaluating new materials, technologies and processes that will help address key sustainability challenges.
  • To mark the anniversary, BASF and CARA hosted a scientific symposium on sustainable transformation in chemistry on April 22.
  • Since 2014, the collaboration has expanded to 11 California universities, including UC Santa Barbara, UC Irvine as well as Stanford University, California Institute of Technology, and University of Southern California.
  • More than 80 faculty members and 170 postdocs/graduate students have worked with BASF and CARA, and BASF has hired 11 postdocs/students from the CARA community.

Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global) 2024

Retrieved on: 
torsdag, april 18, 2024
Infection, University of Southern California, Medical microbiology, University, Mycobacteroides abscessus, Tuberculosis, Epidemiology, ESCMID, ECCMID, Erasmus MC, Urinary tract infection, Science, MAC, Antimycobacterial, Mycobacterium avium complex, Clinical pharmacy, Immunity, TB, National Jewish Health, Division, Pharmaceutical industry

BOSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, today announced that three new pre-clinical studies with NUZYRA® (omadacycline) will be presented at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global, formerly ECCMID).

Key Points: 
  • BOSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, today announced that three new pre-clinical studies with NUZYRA® (omadacycline) will be presented at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global, formerly ECCMID).
  • The hybrid conference will be held April 27-30 at the Fira Gran Via in Barcelona, Spain.
  • “Paratek continues to invest in science to further our understanding of NUZYRA, as well as explore its future utility in addressing additional unmet patient needs,” said Randy Brenner, chief development and regulatory officer of Paratek.
  • “Next week’s ESCMID presentations include a study assessing the potential immunomodulating properties of NUZYRA in addition to its antibacterial activity.

Endeavor BioMedicines to Present New Data From Phase 2a Clinical Trial of ENV-101 at American Thoracic Society 2024 International Conference

Retrieved on: 
onsdag, maj 1, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, University of Southern California, Idiopathic pulmonary fibrosis, University, PPF, ATS, Safety, Randomness, IPF, Conference, Pharming, Therapy, American Thoracic Society, Pharmaceutical industry

Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced that data from a completed Phase 2a clinical trial evaluating the company’s lead investigational candidate ENV-101 in patients with idiopathic pulmonary fibrosis (IPF) will be presented for the first time in a late-breaking oral session at the American Thoracic Society 2024 (ATS 2024) International Conference.

Key Points: 
  • Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced that data from a completed Phase 2a clinical trial evaluating the company’s lead investigational candidate ENV-101 in patients with idiopathic pulmonary fibrosis (IPF) will be presented for the first time in a late-breaking oral session at the American Thoracic Society 2024 (ATS 2024) International Conference.
  • ATS 2024 will take place May 17-22, 2024, in San Diego.
  • The Phase 2a, randomized, double-blind, placebo-controlled clinical trial (NCT04968574) evaluated the safety and efficacy of ENV-101 vs. placebo in 41 patients with confirmed IPF who were treated for 12 weeks.
  • Based on results from the Phase 2a trial of ENV-101, Endeavor BioMedicines intends to initiate a Phase 2 trial in patients with IPF and in a parallel cohort, patients with progressive pulmonary fibrosis (PPF), in 2024.

PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

Retrieved on: 
tisdag, april 16, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, University of Southern California, FDA, Idiopathic pulmonary fibrosis, University, Vital capacity, FVC, Safety, Survival, IPF, CNS, Incidence, Patient, TID, Pirfenidone, Caregiver, Aes, Central nervous system, PRTC, Biomarker, Pharmacology, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that enrollment has been completed in the ELEVATE IPF Phase 2b clinical trial evaluating LYT-100 (deupirfenidone) in patients with idiopathic pulmonary fibrosis (IPF).

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that enrollment has been completed in the ELEVATE IPF Phase 2b clinical trial evaluating LYT-100 (deupirfenidone) in patients with idiopathic pulmonary fibrosis (IPF).
  • This PK profile and the resulting favorable tolerability have been demonstrated across multiple clinical trials in more than 400 individuals.
  • PureTech believes the results of the Phase 2b trial, together with an additional Phase 3 trial, could serve as the basis for registration in the U.S. and other geographies.
  • PureTech would like to extend its gratitude to those participating in the ELEVATE IPF trial, especially the people living with IPF and their caregivers, the clinical trial sites, investigators and advocacy groups.

Federal Judge Orders Return of Million-Dollar Donation After False Prosecution of John Wilson in Varsity Blues Case

Retrieved on: 
måndag, april 22, 2024
ACT, Appeal, Collateral damage, Harvard University, University, IRS, Parent, University of Southern California, White, Varsity, Family, Pressure, Varsity Blues, Court, Republican, USC, Multimedia, Weapon, Student, Government, Pharmaceutical industry

BOSTON, April 22, 2024 /PRNewswire/ -- In a significant ruling, a federal judge has ordered Boston federal prosecutors to return vindicated Varsity Blues parent John Wilson's lawful $1 million donation, which he made to an IRS-certified foundation to support college programs at Harvard and Stanford Universities. This decision comes after Wilson had all the core Varsity Blues charges against him unanimously overturned by the First Circuit Court of Appeals and the government dropped those same charges last year.

Key Points: 
  • In the Varsity Blues case, Singer collaborated with the government to entrap Wilson by crafting a sting operation that deceived him into making a $1 million donation to an IRS-certified charity.
  • Attorney for John Wilson, Michael Kendall of White & Case LLP, released the following statement:
    "John Wilson proved in court that the government should never have included him in the Varsity Blues prosecution.
  • And today the Court agreed to return the lawful donations John made for college programs.
  • The courts have vindicated John Wilson and reversed all the core convictions against him.